Amgen announced Thursday that it reached a global settlement with AbbVie under which it expects to launch Amjevita, its biosimilar version of AbbVie's Humira (adalimumab), in the US on January 31, 2023. Under the deal, which resolves all pending litigation  regarding Amjevita, Amgen is also targeting a launch of the product in Europe, under the name Amgevita, on October 16 next year. Amgen will pay royalties as part of the agreement, although specific financial terms of the deal were not disclosed.
Scott Foraker, general manager of biosimilars at Amgen, remarked "we look forward to leveraging our existing biologics capabilities to bring high-quality biosimilars to patients worldwide." He added that "Amgevita will be one of our first biosimilar launches, and this agreement will allow us to secure a strong foothold in the $4-billion European adalimumab market."
FirstWord reports in this area - Biosimilar Index: A comprehensive drug intelligence service that provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Learn more. 
In May, the US Patent and Trademark Office's Patent Trial and Appeal Board ruled  in favour of Coherus BioSciences concerning the drugmaker's challenge  of a patent covering Humira. The board had previously denied  institution of Coherus' petition challenging a separate patent protecting the therapy.
The FDA approved  Amjevita in September 2016, while European regulators cleared  the biosimilar this past March. For futher analysis, see ViewPoints: AbbVie's biosimilar settlement with Amgen could be decisive .